Jason Kolfenbach

Jason Kolfenbach

Auto-generated profile, based on publicly available information

Jason Kolfenbach

Division of Rheumatology, University of Colorado School of Medicine, Aurora, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Arthritis Care & Research
Verified
Journal Article
Closed access
MBMarcy B. Bolster
Marcy B. Bolster
JKJason Kolfenbach
Jason Kolfenbach
APAlexandra Poeschla
Alexandra Poeschla
LCLisa Criscione‐Schreiber
Lisa Criscione‐Schreiber
FHFaye Hant
Faye Hant
LZLisa Zickuhr
Lisa Zickuhr

1 June 2020 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
ARAmit K. Reddy
Amit K. Reddy
MLMarisa K. Lau
Marisa K. Lau
ESErin G. Sieck
Erin G. Sieck
JKJason R. Kolfenbach
Jason R. Kolfenbach
APAlan G. Palestine
Alan G. Palestine
To describe two cases of retinal artery occlusion followed by contralateral amaurosis fugax associated with eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome). Case 1 is a 57 year-old male who presented with transient vision loss in the right eye two weeks after a cilioretinal artery occlusion in the left eye. Evaluation eventually led to a diagnosis of EGPA. The patient was treated with high-dose steroids followed by systemic immunomodulatory therapy. Vision in the right eye recovered to 20/20 with no further episodes of vision loss. Case 2 is a 55 year-old male with a known diagnosis of EGPA who presented with transient vision loss in the right eye four weeks after a central retinal artery occlusion of the left eye. This patient also successfully recovered vision in the right eye after treatment with high-dose steroids following a change in his systemic immunomodulatory therapy. While ANCA-vasculitides are an uncommon cause of retinal artery occlusion and amaurosis fugax, it is important that they remain in the differential diagnosis, as good visual outcomes can be achieved with prompt initiation of appropriate therapies.

14 January 2025 in Arthritis & Rheumatology
Verified
Journal Article
Open access
GGGeorge E. Georges
George E. Georges
DKDinesh Khanna
Dinesh Khanna
MWMark H. Wener
Mark H. Wener
MMMatthew G. Mei
Matthew G. Mei
MMMAUREEN DAVIDICA MAYES
MAUREEN DAVIDICA MAYES
RNRichard A. Nash
Richard A. Nash
Objective: Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSCs) compared with monthly cyclophosphamide (CY). We asked if an unmodified PBSC graft followed by maintenance mycophenolate mofetil (MMF) after AHSCT, instead of a CD34+ selected graft, could provide comparable AHSCT outcomes.Methods: Twenty patients with high‐risk SSc were enrolled in a prospective, single‐arm trial with CY 200 mg/kg and horse antithymocyte globulin (ATG; CY200/ATG), followed by unmanipulated autologous PBSC, and then MMF maintenance starting at 2 months after AHSCT.Results: Point estimates of OS and EFS at 5 years after AHSCT were 85% (95% confidence interval [CI] 60.4%–94.9%) and 75% (95% CI 50%–88.7%), respectively. Median follow‐up was 7.5 years (range 5.6–11.6) after transplant for living patients. Eight patients (40%) required intensive care unit treatment early after transplant. Early transplant‐related mortality occurred in two patients (10%). Five patients developed relapse/progression of SSc after AHSCT. Four of nine patients with anti‐RNA polymerase III antibodies had prior scleroderma renal crisis and the lowest quartile of estimated glomerular filtration rate (eGFR) on study entry; all four patients developed prolonged organ failure/death early after transplant.Conclusion: We observed favorable OS and EFS after AHSCT for patients with SSc, using CY200/ATG, unmanipulated PBSCs, and MMF posttransplant maintenance, which was comparable to trials with CD34+ graft selection. We identified a possible risk factor, pretransplant low eGFR, for adverse outcomes after AHSCT.

17 August 2021 in Medical Science Educator
Verified
Journal Article
Closed access
PDF file
LZLisa Zickuhr
Lisa Zickuhr
JKJason Kolfenbach
Jason Kolfenbach
MBMarcy B. Bolster
Marcy B. Bolster

21 August 2023 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
RSRachel A. Scott
Rachel A. Scott
SNShane A. Nau
Shane A. Nau
JPJennifer L. Patnaik
Jennifer L. Patnaik
CLChristopher B. Le
Christopher B. Le
JKJason R. Kolfenbach
Jason R. Kolfenbach
ARAmit K. Reddy
Amit K. Reddy
Introduction While phacoemulsification cataract extraction is generally highly effective and safe, patients with a history of uveitis are at higher risk for postoperative complications and often require a modified perioperative medication regimen. No data exists on risks of postoperative complications and persistent anterior uveitis (PAU) in patients with non-ocular autoimmune disease. Methods Medical records were reviewed of patients who underwent phacoemulsification cataract surgery with intraocular lens implantation between January 1, 2014 and December 31, 2019 at the University of Colorado Hospital (UCH) as part of a retrospective cohort study. Exclusion criteria included patient history of ocular inflammation and cataract surgery combined with another intraocular surgery. Patients were only included as having autoimmune disease if the diagnosis was confirmed by a relevant specialist at UCH. Patients with autoimmune disease were then stratified into systemic versus organ-specific autoimmune disease, and patients with systemic autoimmune disease were further stratified into immunosuppressed and not immunosuppressed at the time of cataract surgery. Patients with PAU were identified according to the Standardization of Uveitis Nomenclature Working Group. Data including sex, race/ethnicity, intraoperative cumulative dissipated energy (CDE), and postoperative best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were obtained. Results A total of 422 eyes from 248 patients had confirmed autoimmune disease, compared to a control group of 10,201 eyes. The autoimmune and systemic autoimmune disease groups were not more likely to have postoperative complications or PAU compared to the control group. Immunosuppression status among the systemic autoimmune disease group was also not associated with postoperative complications or PAU. Conclusion Patients with non-ocular autoimmune disease do not appear to be at higher risk for postoperative complications, including worse BCVA or increased rates of IOP elevation and PAU, following phacoemulsification cataract surgery. These patients do not appear to require modification of the typical perioperative medication regimen.

3 January 2025 in Ophthalmology and Therapy
Verified
Journal Article
Open access
PDF file
JSJason Shawver
Jason Shawver
ARAmit K. Reddy
Amit K. Reddy
APAlan G. Palestine
Alan G. Palestine
JKJason R. Kolfenbach
Jason R. Kolfenbach
Introduction Combined uveitis–rheumatology clinics (combined clinics) are a relatively recent clinical care model. Here we report the demographics, ocular and systemic disease characteristics, and medications utilized in patients seen in a combined clinic at a tertiary care hospital in the USA. Methods Medical records were reviewed of patients seen at the Combined Clinic at the University of Colorado Hospital between January 1, 2016 and November 1, 2023. Data including age, sex, referral indication, ocular and systemic inflammatory disease diagnosis, and therapies utilized were obtained. Results A total of 171 patients were included in the study, of which 122 were diagnosed with a systemic inflammatory disease, the most common of which were spondyloarthritis and rheumatoid arthritis. Nearly half of patients referred to the combined clinic with a known ocular inflammatory disease (OID) and suspicion for a systemic process were eventually diagnosed with a systemic disease. The most common associations in patients with both OID and systemic disease were anterior uveitis with spondyloarthritis, and scleritis with rheumatoid arthritis. The most common systemic immunomodulatory therapies (IMT) used were adalimumab, methotrexate, and rituximab. Over 40% of patients underwent a change in IMT during their first evaluation. Conclusions Most patients seen in the combined clinic had both ocular and systemic inflammatory disease and were treated with IMT. Many patients were diagnosed with a systemic inflammatory disease upon evaluation in the combined clinic, and nearly half were recommended to initiate or change IMT at their first visit. This highlights the utility of a combined clinic in the management of these complex patients, in addition to providing logistical benefits to patients and educational opportunities for trainees.